BRIEF-FDA accepts Spectral's expanded access protocol for toraymyxin
June 27 (Reuters) - Spectral Medical Inc
* FDA accepts spectral's expanded access protocol for toraymyxin
* Says expanded access program, sometimes referred to as compassionate use, can now begin at certain of 29 U.S. hospitals
* Says similar program is planned for Canada, where there were 12 hospitals engaged in clinical trial Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)
© Thomson Reuters 2017 All rights reserved.